FGEN

FibroGen (FGEN)

FibroGen Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:FGEN

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/08	00 : 55	AllPennyStocks.com	Traders Rush To Buy Biotech Following Q1 Earnings Beat	NASDAQ:FGEN	FibroGen Inc
2024/05/07	20 : 00	GlobeNewswire Inc.	FibroGen to Participate in Upcoming Investor Conferences	NASDAQ:FGEN	FibroGen Inc
2024/05/07	05 : 10	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:FGEN	FibroGen Inc
2024/05/07	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:FGEN	FibroGen Inc
2024/05/07	05 : 02	GlobeNewswire Inc.	FibroGen Reports First Quarter 2024 Financial Results	NASDAQ:FGEN	FibroGen Inc
2024/04/29	20 : 00	GlobeNewswire Inc.	FibroGen to Report First Quarter 2024 Financial Results	NASDAQ:FGEN	FibroGen Inc
2024/04/25	05 : 02	GlobeNewswire Inc.	FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A	NASDAQ:FGEN	FibroGen Inc
2024/04/03	06 : 46	GlobeNewswire Inc.	FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer	NASDAQ:FGEN	FibroGen Inc
2024/03/26	20 : 00	GlobeNewswire Inc.	FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference	NASDAQ:FGEN	FibroGen Inc
2024/03/11	20 : 00	GlobeNewswire Inc.	FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer	NASDAQ:FGEN	FibroGen Inc
2024/03/09	09 : 19	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:FGEN	FibroGen Inc
2024/03/09	09 : 18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:FGEN	FibroGen Inc
2024/03/09	09 : 17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:FGEN	FibroGen Inc
2024/02/27	06 : 08	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:FGEN	FibroGen Inc
2024/02/27	06 : 06	GlobeNewswire Inc.	FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:FGEN	FibroGen Inc
2024/02/27	06 : 05	GlobeNewswire Inc.	FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea	NASDAQ:FGEN	FibroGen Inc
2024/02/24	10 : 33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:FGEN	FibroGen Inc
2024/02/24	10 : 29	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:FGEN	FibroGen Inc
2024/02/24	10 : 28	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:FGEN	FibroGen Inc
2024/02/20	21 : 00	GlobeNewswire Inc.	FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:FGEN	FibroGen Inc
2024/02/15	05 : 37	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:FGEN	FibroGen Inc
2024/02/06	10 : 08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:FGEN	FibroGen Inc
2024/02/05	21 : 00	GlobeNewswire Inc.	FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024	NASDAQ:FGEN	FibroGen Inc
2024/01/25	21 : 00	GlobeNewswire Inc.	FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer	NASDAQ:FGEN	FibroGen Inc
2023/12/27	09 : 28	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:FGEN	FibroGen Inc
2023/12/12	06 : 21	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:FGEN	FibroGen Inc
2023/12/12	06 : 20	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:FGEN	FibroGen Inc
2023/12/12	06 : 19	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:FGEN	FibroGen Inc
2023/12/10	07 : 02	GlobeNewswire Inc.	FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting	NASDAQ:FGEN	FibroGen Inc
2023/11/07	06 : 11	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:FGEN	FibroGen Inc